A new study from the Yale School of Public Health and other research centers has found that a diabetes drug called rosiglitazone may increase the risk of serious heart problems.
This medicine is used to help people with type 2 diabetes manage their blood sugar levels. It belongs to a group of drugs known as thiazolidinediones.
While rosiglitazone can help control blood sugar, it has also been at the center of a long debate about its safety. Some experts have worried for years that it may increase the chances of having heart attacks or other heart-related issues. Because of these concerns, the drug was suspended in Europe, and its use was limited in the United States.
Since 2007, researchers have tried to understand whether rosiglitazone truly raises the risk of heart problems. Many studies have been done, but the results have been mixed. One reason for the confusion was that earlier research didn’t have access to detailed data from each individual patient, making it harder to clearly see the risks.
This new study is the most complete analysis of rosiglitazone’s heart risks so far. The researchers looked at data from more than 130 clinical trials that involved over 48,000 adults. Everyone in the study had taken the drug for at least 24 weeks. The researchers compared people who took rosiglitazone to those who received a placebo or a different treatment.
The results were concerning. The study found that people who took rosiglitazone had a 33% higher chance of having a serious heart-related event. This included heart attacks, heart failure, or even death from heart-related or other causes.
To break it down further, there were 274 cardiovascular events among 11,837 people who took rosiglitazone. In comparison, there were 219 such events among 9,319 people in the control group who did not take the drug.
The researchers say this study highlights the need for using detailed patient data to understand the safety of medications. It also shows why transparency and data sharing in clinical trials are so important. When doctors and researchers have access to more complete information, they can better understand the risks and make safer choices for patients.
Rosiglitazone is still available in some countries, but these new findings may lead to more questions about whether it should continue to be used. People who are currently taking this drug should talk with their doctors. It’s important to weigh the benefits and risks and ask about safer options if needed.
This study was published in the medical journal BMJ. It serves as a reminder of how important it is to monitor diabetes medications not just for how well they control blood sugar, but also for how they affect heart health over time.
If you care about diabetes, please read studies about This drug combo can treat type 2 diabetes in the long run effectively and findings of Eating fewer than 3 meals a day may help reduce risk of type 2 diabetes and obesity.
For more about diabetes, please read studies about How to choosing the right fruits for type 2 diabetes and findings of New higher dose diabetes drug promises better blood sugar control and weight loss.
Copyright © 2025 Knowridge Science Report. All rights reserved.
